• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ovid Therapeutics Inc (NQ: OVID )

    1.058 +0.048 (+4.78%)
    Streaming Delayed Price Updated: 1:38 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 157,751
    Open 1.030
    Bid (Size) 1.050 (6)
    Ask (Size) 1.060 (89)
    Prev. Close 1.010
    Today's Range 1.000 - 1.060
    52wk Range 0.6800 - 4.139
    Shares Outstanding 70,417,345
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
    Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain 
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    7 Sorry Biotech Stocks Set to Make Investors Sad
    Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
    Via InvestorPlace

    Performance

    YTD
    -68.12%
    -68.12%
    1 Month
    +33.96%
    +33.96%
    3 Month
    -66.40%
    -66.40%
    6 Month
    -70.10%
    -70.10%
    1 Year
    -69.76%
    -69.76%

    More News

    Read More
    eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
    Via Benzinga
    Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Nasdaq Surges Over 200 Points; Aaron's Shares Jump
    Via Benzinga
    Is the Stock Market Closed on Juneteenth 2024?
    Via InvestorPlace
    ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
    Via InvestorPlace
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
    Via InvestorPlace
    Why Is Ovid Therapeutics (OVID) Stock Down 69% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Mixed; Dow Tumbles Over 100 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
    Via Benzinga
    Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    3 Sorry Penny Stocks to Sell in May While You Still Can
    Via InvestorPlace
    Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
    Via InvestorPlace
    OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Ovid Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.